(Q57088961)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15717025%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

review article

1 reference

title

Neuroimaging in Parkinson's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15717025%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15717025%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

author name string

David J Brooks

series ordinal

1

0 references

language of work or name

English

0 references

publication date

1 April 2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15717025%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15717025%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15717025%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15717025%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

page(s)

243-254

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15717025%20AND%20SRC:MED&resulttype=core&format=json

A comparison of (18)F-dopa PET and inversion recovery MRI in the diagnosis of Parkinson's disease

8 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Ageing and Parkinson's disease: substantia nigra regional selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Clinical and [18F] dopa PET findings in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Dopaminergic innervation of the globus pallidus by collaterals from the nigrostriatal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Plasticity of the nigropallidal pathway in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

[11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

[123I] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

[(11)C, (127)I] Altropane: a highly selective ligand for PET imaging of dopamine transporter sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Relationship between clinical features of Parkinson's disease and presynaptic dopamine transporter binding assessed with [123I]IPT and single-photon emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Dopaminergic function in familial Parkinson's disease: A clinical and18F-dopa positron emission tomography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Effect of treatment with L-dopa/carbidopa or L-selegiline on striatal dopamine transporter SPECT imaging with [123I]beta-CIT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Longitudinal fluorodopa positron emission tomographic studies of the evolution of idiopathic parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Rate of progression in Parkinson's disease: a 6-[18F]fluoro-L-dopa PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

[123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

[123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Slowing Parkinson's disease progression: recent dopamine agonist trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Cerebral implantation in movement disorders: state of the art.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

[11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Motor correlates of occipital glucose hypometabolism in Parkinson's disease without dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Dementia in Parkinson's disease.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534937

Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534937

Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534937

Progression in Parkinson's disease: a positron emission tomography study with a dopamine transporter ligand [18F]CFT.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534937

Striatal uptake of a novel PET ligand, [18F]beta-CFT, is reduced in early Parkinson's disease.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534937

Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534937

The genetics of Parkinson's disease: a reconsideration

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534937

Effects of dopamine denervation on striatal peptide expression in parkinsonian monkeys.

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534937

In vivo and in vitro studies of the dopaminergic system in movement disorders

2 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=534937

Differentiation of atypical parkinsonian syndromes with routine MRI

2 November 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Striatal uptake of a novel PET ligand, [18F]?-CFT, is reduced in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

PK ('peripheral benzodiazepine')--binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Dopamine agonists and neuroprotection in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

The metabolic topography of parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1602%2FNEURORX.1.2.243

Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers

21 January 2018

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET

1 reference

PubMed

12 December 2020

Identifiers

DOI

10.1602/NEURORX.1.2.243

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15717025%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15717025%20AND%20SRC:MED&resulttype=core&format=json

8 January 2020

PubMed publication ID

15717025

1 reference